- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024$21.7 (-1.05%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024$19.03Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023$19.64 (-1.13%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023$27.16Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023$27.94Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023$25.25Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019Earnings
Q1 2024 BioArctic AB Earnings Call Transcript
Thank you. Good morning, and welcome to BioArctic's presentation for the first quarter of 2024. It's very exciting times for BioArctic with LEQEMBI, which is originating from BioArctic. LEQEMBI is the first and only disease-modifying treatment for Alzheimer's disease with a full approval so far in the US, Japan and China. There will be three key messages today. I'll talk about the LEQEMBI sales, which we see is increasing. The infrastructure has been established to a large extent in the US and the launch goes now to the next expansion phase.
The second part is that the lecanemab regulatory processes continues with more approvals and China was approved early this year and more submissions are also being filed by A5, including a subcutaneous auto injector file. The third aspect and key message is also around the rest of our portfolio, which is progressing really well, and we have made our first agreement on a project which is utilizing our BrainTransporter technology. And I'll talk more about all this here today.
Next slide, please. I'm
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)